Articles by Antonio Cano, MD

Frequency of FRAX risk factors in osteopenic postmenopausal women with and without history of fragility fracture

Baró, Francesc; Cano, Antonio; Sánchez Borrego, Rafael; More

Menopause. 19(11):1193-1199, November 2012.

  • Editorial

The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study

Cano, Antonio; Estévez, José; Usandizaga, Ramón; More

Menopause. 19(10):1130-1139, October 2012.

Effects of administration of hormone therapy or raloxifene on the immune system and on biochemical markers of bone remodeling

Pineda, Begoña; Hermenegildo, Carlos; Tarín, Juan J.; More

Menopause. 19(3):319-327, March 2012.

Relationship of sclerostin and secreted frizzled protein polymorphisms with bone mineral density: an association study with replication in postmenopausal women

Valero, Carmen; Zarrabeitia, María T.; Hernández, José L.; More

Menopause. 18(7):802-807, July 2011.

Transdermal estradiol reduces F2α-isoprostane levels in postmenopausal women

Hermenegildo, Carlos; Oviedo, Pilar J.; Laguna, Andrés; More

Menopause. 15(4):714-717, July-August 2008.

Hormonal environment in the induction of breast cancer in castrated rats using dimethylbenzanthracene: influence of the presence or absence of ovarian activity and of treatment with estradiol, tibolone, and raloxifene

Callejo, Justo; Cano, Antonio; Medina, Marilyn; More

Menopause. 12(5):601-608, September-October 2005.

Raloxifene increases the capacity of serum to promote prostacyclin release in human endothelial cells: implication of COX-1 and COX-2

Oviedo, Pilar J.; Hermenegildo, Carlos; Cano, Antonio

Menopause. 11(4):430-437, July-August 2004.